본문 바로가기
KERD
논문KCI 등재

Immune Activation and Gut Microbes in Irritable Bowel Syndrome

Khaldun Al-Khatib|Henry C. Lin
거트앤리버 소화기연관학회협의회|2009.03|Gut and Liver|제3권 제1호|pp. 14-19

2

조회

0

다운로드

2

인용

0

참고문헌

초록

Irritable bowel syndrome (IBS) is a highly prevalent disorder that is characterized by chronic abdominal pain and altered bowel habit. The diagnosis of IBS has traditionally been made by matching the complaints of the patient with established clinical criteria, since the underlying pathophysiology was not known. Various new findings have recently been reported in IBS patients that challenge our concept of IBS as a syndrome with no explanation. While the florid inflammation characteristic of inflammatory bowel disease is absent in IBS, changes suggesting immune activation are present in nearly all IBS patients. Is IBS an autoimmune disease, or is the immune activation responding to a trigger? In this review we present evidence that points to a state of immune activation in IBS and show data that suggest that small intestinal bacterial overgrowth triggers immune activation in IBS.

Abstract

Irritable bowel syndrome (IBS) is a highly prevalent disorder that is characterized by chronic abdominal pain and altered bowel habit. The diagnosis of IBS has traditionally been made by matching the complaints of the patient with established clinical criteria, since the underlying pathophysiology was not known. Various new findings have recently been reported in IBS patients that challenge our concept of IBS as a syndrome with no explanation. While the florid inflammation characteristic of inflammatory bowel disease is absent in IBS, changes suggesting immune activation are present in nearly all IBS patients. Is IBS an autoimmune disease, or is the immune activation responding to a trigger? In this review we present evidence that points to a state of immune activation in IBS and show data that suggest that small intestinal bacterial overgrowth triggers immune activation in IBS.

참고문헌 (46)

  1. Drossman DA, "US householder survey of functional gastrointestinal disorders: prevalence, sociodemography, and health impact", Dig Dis Sci, 38, pp.1569~1580 (1993)
  2. Drossman DA, "AGA technical review on irritable bowel syndrome", Gastroenterology, 123, pp.2108~2131 (2002)
  3. Collins SM, "A case for immunological basis for irritable bowel syndrome", Gastroenterology, 122, pp.2078~2080 (2002)
  4. Neal KR, "Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients", BMJ, 314, pp.779~782 (1997)
  5. Spiller RC, "Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome", Gut, 47, pp.804~811 (2000)
  6. McKendrick M, "Irritable bowel syndrome: post salmonella infection", J Infect, 29, pp.1~3 (1994)
  7. Cumberland P, "The infectious intestinal disease study of England: a prospective evaluation of symptoms and health care use after an acute episode", Epidemiol Infect, 130, pp.453~460 (2003)
  8. Harvey R, "Prognosis in the irritable bowel syndrome: a 5-year prospective study", Lancet, 1, pp.963~965 (1987)
  9. Bercik P, "Is irritable bowel syndrome a low grade inflammatory bowel disease?", Gastroenterol Clin North Am, 34, pp.235~245 (2005)
  10. Gwee KA, "The role of psychological and biological factors in postinfective gut dysfunction", Gut, 44, pp.400~406 (1999)
  11. Chadwick V, "Activation of the mucosal immune system in irritable bowel syndrome", Gastroenterology, 122, pp.1778~1783 (2002)
  12. Holmén N, "CD4＋CD25＋ regulatory T cells in irritable bowel syndrome patients", Neurogastroenterol Motil, 19, pp.119~125 (2007)
  13. Ricciardelli I, "Anti tumour necrosis-alpha therapy increases the number of FOXP3＋ regulatory T cells in children affected by Crohn's disease", Immunology, 125, pp.178~183 (2008)
  14. Tornblom H, "Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome", Gastroenterology, 123, pp.1972~1979 (2002)
  15. Plaisancié P, "Effects of neurotransmitters, gut hormones, and inflammatory mediators on mucus discharge in rat colon", Am J Physiol, 275, pp.G1073~1084 (1998)
  16. Kuwahara A, "5-HT activates nitric oxide-generating neurons to stimulate chloride secretion in guinea pig distal colon", Am J Physiol, 275, pp.G829~834 (1998)
  17. Frieling T, "Effects of the inflammatory mediator prostaglandin D2 on submucosal neurons and secretion in guinea pig colon", Am J Physiol, 266, pp.G132~139 (1994)
  18. Langhorst J, "Activated innate immune system in irritable bowel syndrome?", Gut, 56, pp.1325~1326 (2007)
  19. Dinan TG, "Hypothalamicpituitary- gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?", Gastroenterology, 130, pp.304~311 (2006)
  20. Murphy K, "Janeway’s Immunobiology. 7th ed" (2007), Garland Science
  21. Liebregts T, "Immune activation in patients with irritable bowel syndrome", Gastroenterology, 132, pp.913~920 (2007)
  22. Collins S, "The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders", Gastroenterology, 111, pp.1683~1699 (1996)
  23. Aerssens J, "Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome", Clin Gastroenterol Hepatol, 6, pp.194~205 (2008)
  24. Weston AP, "Terminal ileal mucosal mast cellls in irritable bowel syndrome", Dig Dis Sci, 38, pp.1590~1595 (1993)
  25. Talley NJ, "Mast cell infiltration and degranulation in colonic mucosa in the irritable bowel syndrome", Am J Gastroenterol, 91, pp.1675~1676 (1996)
  26. O'Sullivan M, "Increased mast cells in the irritable bowel syndrome", Neurogastronterol Motil, 12, pp.449~457 (2000)
  27. Cenac N, "Induction of intestinal inflammation in mouse by activation of proteinase- activated receptor-2", Am J Pathol, 161, pp.1903~1915 (2002)
  28. Barbara G, "Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome", Gastroenterology, 126, pp.693~702 (2004)
  29. Roka R, "A pilot study of fecal serine-protease activity: a pathophysiologic factor in diarrhea-predominant irritable bowel syndrome", Clin Gastroenterol Hepatol, 5, pp.550~555 (2007)
  30. Roka R, "Colonic luminal proteases activate colonocyte proteinase-activated receptor-2 and regulate paracellular permeability in mice", Neurogastroenterol Motil, 19, pp.57~65 (2007)
  31. Kyosola K, "Rectal mucosal adrenergic innervation and enterochromaffin cells in ulcerativecolitis and irritable colon", Scand J Gastroenterol, 12, pp.363~367 (1977)
  32. Dunlop SP, "Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in post-infectious IBS", Gastroenterology, 125, pp.1651~1659 (2003)
  33. Gershon M, "Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel", Aliment Pharmacol Ther, 13(2), pp.15~30 (1999)
  34. Linden D, "Serotonin availability is increased in mucosa of guinea pigs with TNBS-induced colitis", Am J Physiol Gastrointest Liver Physiol, 285, pp.G207~216 (2003)
  35. Bearcroft C, "Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study", Gut, 42, pp.42~46 (1998)
  36. Bosedovsky H, "The immune response evokes changes in brain noradrenergic neurons", Science, 221, pp.564~566 (1983)
  37. Lin HC, "Small intestinal bacterial overgrowth: a framework for understanding IBS", JAMA, 292, pp.852~858 (2004)
  38. Chang L, "Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis in irritable bowel syndrome", Neurogastroenterol Motil (2008)
  39. Elsenbruch S, "Are there alterations of neuroendocrine and cellular immune responses to nutrients in women with irritable bowel syndrome", Am J Gastroenterol, 99, pp.703~710 (2004)
  40. Pimentel M, "Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo- controlled study", Am J Gastroenterol, 98, pp.412~419 (2003)
  41. Pimentel M, "The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial", Ann Intern Med, 145, pp.557~563 (2006)
  42. Schoepfer AM, "Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients", Neurogastroenterol Motil, 20, pp.1110~1118 (2008)
  43. O'Mahony L, "Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice", Aliment Pharmacol Ther, 15, pp.1219~1225 (2001)
  44. McCarthy J, "Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance", Gut, 52, pp.975~980 (2003)
  45. O'Mahony L, "Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles", Gastroenterology, 128, pp.541~551 (2005)
  46. Pimentel M, "A new rat model links two contemporary theories in irritable bowel syndrome", Dig Dis Sci, 53, pp.982~989 (2008)

관련 논문AI추천

Gut Microbiota as Potential Orchestrators of Irritable Bowel SyndromeLena Öhman, Magnus Simrén, Sean M.P. Bennet거트앤리버 소화기연관학회협의회 · Gut and Liver2015 · 제9권 제3호Cellular and Molecular Basis of Intestinal Barrier Dysfunction in the Irritable Bowel SyndromeAna Gonzalez-Castro, Cristina Martínez, Javier Santos, Maria Vicario거트앤리버 소화기연관학회협의회 · Gut and Liver2012 · 제6권 제3호Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic DichotomyRatnakar Shukla, Uday C Ghoshal, Ujjala Ghoshal거트앤리버 소화기연관학회협의회 · Gut and Liver2017 · 제11권 제2호Dietary modulation of gut microbiota for the relief of irritable bowel syndrome김미영, 최상운한국영양학회 · Nutrition Research and Practice2021 · 제15권 제4호The Relationship between Small-Intestinal Bacterial Overgrowth and Intestinal Permeability in Patients with Irritable Bowel Syndrome김병익, 김홍주, 박동일, 박정호, 손정일, 전우규, 조용균, Kyoung Hee Won, Soon Min Park거트앤리버 소화기연관학회협의회 · Gut and Liver2009 · 제3권 제3호Compositional and Functional Changes in the Gut Microbiota in Irritable Bowel Syndrome PatientsChoi Soo In, Kim Nayoung, Kim Yong Sung, Lee Dong Ho, Lee Sun Min, Park Ji Hyun, Yoon Hyuk거트앤리버 소화기연관학회협의회 · Gut and Liver2021 · 제15권 제2호

이 간행물의 다른 논문 (11건)

Optimizing the Dose and Duration of Therapy for Chronic Hepatitis CSamuel B. Ho, Nipaporn Pichetshote, Erik Groessl, Helen Yeepp. 1-13Recombinant Interferon-Beta-1α Plus Ribavirin for the Treatment of Chronic HCV Infection: A Prospective, Randomized, Comparative Pilot StudyYong Soo Kim, Ja Kyung Kim, Chae Yoon Chon, Young Myoung Moon, Hyun Woong Lee, 안상훈, Kwang-Hyub Hanpp. 20-25Plasma 5-Hydroxytryptamine Concentration and Its Correlation with Psychopathology in Patients with Irritable Bowel Syndrome김현수, 유종선, 최성규, 조성범, Chang-Hwan Park, 이완식, Seon-Young Park, Kyoung-Won Yoon, Min-Ho Parkpp. 26-30Treatment of Gastric Candidiasis in Patients with Gastric Ulcer Disease: Are Antifungal Agents Necessary?탁원영, 정민규, 김성국, 최용환, 전성우, 권영오, 조창민pp. 31-34Colorectal Neoplasm in Asymptomatic Average-risk Koreans: The KASID Prospective Multicenter Colonoscopy Survey진윤태, 최황, Suk-Kyun Yang, 변정식, Jai Hyun Choi, Hye-Won Park, Moon Sung Lee, Il-Kwon Chung, Jae Suk Song, 김현수, 박동일, 정성애, 김태일, 김원호, 한동수, 김효종, Young-Ho Kim, 최규용pp. 35-40
원문 보기